Terrie Curran, Phathom CEO (Credit: Arcutis)
Phathom's old Takeda drug bests Prevacid in a PhIII GI trial. Next stop? The FDA
There’s no time for rest in biopharma — at least not at Phathom Pharmaceuticals. Just over a month after submitting two NDAs for its lead acid …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
